Sophie Iochmann
Iochmann, Sophie
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 210282715 ( Personal )
Permalink: http://viaf.org/viaf/210282715
Preferred Forms
-
100 1 _
‡a
Iochmann, Sophie
-
100 1 _
‡a
Iochmann, Sophie
-
100 0 _
‡a
Sophie Iochmann
4xx's: Alternate Name Forms (2)
Works
| Title | Sources |
|---|---|
| The 20210A allele of the prothrombin gene is not a risk factor for retinal vein occlusion |
|
| Angiogenesis stimulated by human kallikrein-related peptidase 12 acting via a platelet-derived growth factor B-dependent paracrine pathway |
|
| CCL5-enhanced human immature dendritic cell migration through the basement membrane in vitro depends on matrix metalloproteinase-9. |
|
| Computer model of the interaction of human TFPI-2 Kunitz-type serine protease inhibitor with human plasmin |
|
| Demonstration of inducible TFPI-2 mRNA synthesis in BeWo and JEG-3 trophoblast cells using a competitive RT-PCR. |
|
| Fast detection of tissue factor and tissue factor pathway inhibitor messenger RNA in endothelial cells and monocytes by sensitive reverse transcription-polymerase chain reaction |
|
| Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor |
|
| Human allogeneic lymphocytes trigger endothelial cell tissue factor expression by a tumor necrosis factor-dependent pathway |
|
| Human choriocarcinoma cell resistance to natural killer lysis due to defective triggering of natural killer cells. |
|
| Immunothérapie et immunoprophylaxie de la cryptosporidiose : expression de la protéine de 15/17 kda de Cryptosporium parvum en système procaryote et eucaryote et étude de la réponse immunitaire vis-a-vis de cette protéine recombinante |
|
| Impact of a serine proteinase inhibitor expression, TFPI-2 (Tissue Factor Pathway Inhibtor-2 on the tumoral pulmonary microenvironment. |
|
| Improved PCR method for amplification of GC-rich DNA sequences. |
|
| Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. |
|
| Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. |
|
| Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. |
|
| Major antigens of Cryptosporidium parvum recognised by serum antibodies from different infected animal species and man. |
|
| Monitoring of tumour progression using bioluminescence imaging and computed tomography scanning in a nude mouse orthotopic model of human small cell lung cancer. |
|
| Nasal immunization of mice with Cryptosporidium parvum DNA induces systemic and intestinal immune responses |
|
| Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays. |
|
| Rôle du TFPI-2, un inhibiteur de protéases à sérine, dans la progression des cancers broncho-pulmonaires à petites cellules |
|
| TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions. |
|
| Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. |
|
| Transcriptional silencing of the TFPI-2 gene by promoter hypermethylation in choriocarcinoma cells. |
|
